{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:56:52Z","timestamp":1793923012999,"version":"4.8.0"},"reference-count":186,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Treatment-resistant schizophrenia (TRS) is often associated with severe burden of disease, poor quality of life and functional impairment. Clozapine is the gold standard for the treatment of TRS, although it is also known to cause significant side effects in some patients. In view of the burgeoning interest in the role of genetic factors in precision psychiatry, we conducted a scoping review to narratively summarize the current genetic factors associated with TRS, clozapine resistance and side effects to clozapine treatment. We searched PubMed from inception to December 2022 and included 104 relevant studies in this review. Extant evidence comprised associations between TRS and clozapine resistance with genetic factors related to mainly dopaminergic and serotoninergic neurotransmitter systems, specifically, TRS and rs4680, rs4818 within COMT, and rs1799978 within DRD2; clozapine resistance and DRD3 polymorphisms, CYP1A2 polymorphisms; weight gain with LEP and SNAP-25 genes; and agranulocytosis risk with HLA-related polymorphisms. Future studies, including replication in larger multi-site samples, are still needed to elucidate putative risk genes and the interactions between different genes and their correlations with relevant clinical factors such as psychopathology, psychosocial functioning, cognition and progressive changes with treatment over time in TRS and clozapine resistance.<\/jats:p>","DOI":"10.3390\/genes14030689","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T06:09:56Z","timestamp":1678687796000},"page":"689","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8503-8240","authenticated-orcid":false,"given":"Jiangbo","family":"Ying","sequence":"first","affiliation":[{"name":"East Region, Institute of Mental Health, Singapore 539747, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0969-7994","authenticated-orcid":false,"given":"Qian Hui","family":"Chew","sequence":"additional","affiliation":[{"name":"Research Division, Institute of Mental Health, Singapore 539747, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Department of PsychiSatry, University of Toronto, Toronto, ON M5R 0A3, Canada"},{"name":"Brain and Cognition Discovery Foundation Toronto, Toronto, ON M4W 3W4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3209-9626","authenticated-orcid":false,"given":"Kang","family":"Sim","sequence":"additional","affiliation":[{"name":"West Region, Institute of Mental Health, Singapore 539747, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"St\u0119pnicki, P., Kondej, M., and Kaczor, A.A. (2018). Current Concepts and Treatments of Schizophrenia. Molecules, 23.","DOI":"10.3390\/molecules23082087"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr. Bull."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/schbul\/sbm061","article-title":"Outpatient antipsychotic treatment and inpatient costs of schizophrenia","volume":"34","author":"Marcus","year":"2008","journal-title":"Schizophr. Bull."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.psc.2016.01.006","article-title":"Treatment-Resistant Schizophrenia","volume":"39","author":"Elkis","year":"2016","journal-title":"Psychiatr. Clin. North Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","article-title":"The social and economic burden of treatment-resistant schizophrenia: A systematic literature review","volume":"29","author":"Kennedy","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pnpbp.2015.08.010","article-title":"Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones","volume":"65","author":"Iasevoli","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S2215-0366(19)30132-4","article-title":"The Lancet Psychiatry Commission: A blueprint for protecting physical health in people with mental illness","volume":"6","author":"Firth","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-019-0090-z","article-title":"The neurobiology of treatment-resistant schizophrenia: Paths to antipsychotic resistance and a roadmap for future research","volume":"6","author":"Potkin","year":"2020","journal-title":"NPJ Schizophr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000112883","article-title":"Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes","volume":"77","author":"Chouinard","year":"2008","journal-title":"Psychother. Psychosom."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1176\/ajp.135.11.1409","article-title":"Neuroleptic-induced supersensitivity psychosis","volume":"135","author":"Chouinard","year":"1978","journal-title":"Am. J. Psychiatry"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.biopsych.2013.06.011","article-title":"Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function","volume":"75","author":"Demjaha","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"pyu117","DOI":"10.1093\/ijnp\/pyu117","article-title":"Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia","volume":"18","author":"Goldstein","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0010-440X(66)80028-7","article-title":"Therapeutic studies in \"therapy resistant\" schizophrenic patients","volume":"7","author":"Itil","year":"1966","journal-title":"Compr. Psychiatry"},{"key":"ref_14","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"Galletly","year":"2016","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: Recommendations from the British Association for Psychopharmacology","volume":"25","author":"Barnes","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/bs.apha.2017.09.009","article-title":"Unique Effects of Clozapine: A Pharmacological Perspective","volume":"82","author":"Khokhar","year":"2018","journal-title":"Adv. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/ajp.156.7.990","article-title":"Evidence of clozapine\u2019s effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials","volume":"156","author":"Wahlbeck","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","article-title":"Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials","volume":"158","author":"Chakos","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1176\/appi.ps.201700162","article-title":"Addressing Barriers to Clozapine Underutilization: A National Effort","volume":"69","author":"Kelly","year":"2018","journal-title":"Psychiatr. Serv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s00277-020-04215-y","article-title":"Clozapine-induced agranulocytosis","volume":"99","author":"Mijovic","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-1625-6388","article-title":"An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels","volume":"55","author":"Schoretsanitis","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1007\/s12031-021-01866-y","article-title":"Interacting Roles of COMT and GAD1 Genes in Patients with Treatment-Resistant Schizophrenia: A Genetic Association Study of Schizophrenia Patients and Healthy Controls","volume":"71","author":"Kogure","year":"2021","journal-title":"J. Mol. Neurosci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s11033-021-07019-z","article-title":"A preliminary genetic association study of GAD1 and GABAB receptor genes in patients with treatment-resistant schizophrenia","volume":"49","author":"Miyazawa","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/NDT.S228103","article-title":"The CYP2C19*2 and CYP2C19*17 Polymorphisms Influence Responses to Clozapine for the Treatment of Schizophrenia","volume":"16","author":"Semedo","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/hup.2408","article-title":"Polymorphism in alpha 2A adrenergic receptor gene is associated with sialorrhea in schizophrenia patients on clozapine treatment","volume":"29","author":"Solismaa","year":"2014","journal-title":"Hum. Psychopharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Hajj, A., Obeid, S., Sahyoun, S., Haddad, C., Azar, J., Rabbaa Khabbaz, L., and Hallit, S. (2019). Clinical and Genetic Factors Associated with Resistance to Treatment in Patients with Schizophrenia: A Case-Control Study. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194753"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3389\/fphar.2018.00705","article-title":"Haplotypic and Genotypic Association of Catechol-O-Methyltransferase rs4680 and rs4818 polymorphisms and treatment resistance in schizophrenia","volume":"9","author":"Sagud","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.gene.2014.03.050","article-title":"Treatment-resistant schizophrenia and DAT and SERT polymorphisms","volume":"543","author":"Bilic","year":"2014","journal-title":"Gene"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/ijnp\/pyac025","article-title":"Polymorphisms in Schizophrenia-Related Genes Are Potential Predictors of Antipsychotic Treatment Resistance and Refractoriness","volume":"25","author":"Zazueta","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2147\/NDT.S176455","article-title":"Association study between","volume":"14","author":"Escamilla","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat"},{"key":"ref_34","first-page":"141","article-title":"T102C polymorphism in the 5HT2A gene and schizophrenia: Relation to phenotype and drug response variability","volume":"24","author":"Joober","year":"1999","journal-title":"J. Psychiatry Neurosci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fpsyt.2019.00058","article-title":"Association of Serotonin","volume":"10","author":"Li","year":"2019","journal-title":"Front. Psychiatry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hup.1163","article-title":"Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia","volume":"26","author":"Bishop","year":"2011","journal-title":"Hum. Psychopharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1007\/s12035-018-0876-4","article-title":"Accessing Gene Expression in Treatment-Resistant Schizophrenia","volume":"55","author":"Moretti","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1007\/s12031-020-01772-9","article-title":"Expression of BDNF-Associated lncRNAs in Treatment-Resistant Schizophrenia Patients","volume":"71","author":"Badrlou","year":"2021","journal-title":"J. Mol. Neurosci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.schres.2013.01.020","article-title":"Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia","volume":"146","author":"Zhang","year":"2013","journal-title":"Schizophr. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1038\/s41380-020-0791-8","article-title":"Clozapine modulates retinoid homeostasis in human brain and normalizes serum retinoic acid deficit in patients with schizophrenia","volume":"26","author":"Regen","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_41","first-page":"246","article-title":"Exploratory analysis of rare and novel variants in mexican patients diagnosed with schizophrenia and dementia","volume":"71","author":"Lanzagorta","year":"2019","journal-title":"Rev. Investig. Clin."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.schres.2014.08.018","article-title":"A genetic locus in 7p12.2 associated with treatment resistant schizophrenia","volume":"159","author":"Li","year":"2014","journal-title":"Schizophr Res"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Pinheiro, D.S., Santos, R.D.S., de Brito, R.B., Cruz, A.H.D.S., Ghedini, P.C., and Reis, A.A.S. (2017). GSTM1\/GSTT1 double-null genotype increases risk of treatment-resistant schizophrenia: A genetic association study in Brazilian patients. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183812"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000507670","article-title":"Differential Methylation Pattern of Schizophrenia Candidate Genes in Tetrahydrocannabinol-Consuming Treatment-Resistant Schizophrenic Patients Compared to Non-Consumer Patients and Healthy Controls","volume":"80","author":"Jahn","year":"2021","journal-title":"Neuropsychobiology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"346","DOI":"10.17712\/nsj.2021.4.20200050","article-title":"Investigation of inflammation related gene polymorphism of the mannose-binding lectin 2 in schizophrenia and bipolar disorder","volume":"26","author":"Aytac","year":"2021","journal-title":"Neurosciences"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.psychres.2016.08.037","article-title":"miR-181b-5p, miR-195-5p and miR-301a-3p are related with treatment resistance in schizophrenia","volume":"245","author":"Alacam","year":"2016","journal-title":"Psychiatry Res."},{"key":"ref_47","first-page":"4340","article-title":"Investigating aberrantly expressed microRNAs in peripheral blood mononuclear cells from patients with treatment-resistant schizophrenia using miRNA sequencing and integrated bioinformatics","volume":"22","author":"You","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Funahashi, Y., Yoshino, Y., Iga, J.I., and Ueno, S.I. (2022). Impact of clozapine on the expression of miR-675-3p in plasma exosomes derived from patients with schizophrenia. World J. Biol. Psychiatry, 1\u201311.","DOI":"10.1080\/15622975.2022.2104924"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.biopsych.2022.03.012","article-title":"miR143-3p-Mediated NRG-1-Dependent Mitochondrial Dysfunction Contributes to Olanzapine Resistance in Refractory Schizophrenia","volume":"92","author":"Sun","year":"2022","journal-title":"Biol. Psychiatry"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3389\/fpsyt.2017.00225","article-title":"Peripheral Transcription of","volume":"8","author":"Mostaid","year":"2017","journal-title":"Front. Psychiatry"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajmg.b.30191","article-title":"Population-based and family-based association study of 5\u2019UTR polymorphism of the reelin gene and schizophrenia","volume":"137B","author":"Goldberger","year":"2005","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neulet.2004.12.037","article-title":"The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia","volume":"379","author":"Klempan","year":"2005","journal-title":"Neurosci. Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/08820139.2020.1832115","article-title":"Tumor Necrosis Factor-alpha (TNF-\u03b1) -238 G\/A Polymorphism Is Associated with the Treatment Resistance and Attempted Suicide in Schizophrenia","volume":"51","author":"Aytac","year":"2022","journal-title":"Immunol. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jpsychires.2019.03.005","article-title":"Blood and brain protein levels of ubiquitin-conjugating enzyme E2K (UBE2K) are elevated in individuals with schizophrenia","volume":"113","author":"Meiklejohn","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/npp.2016.258","article-title":"Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study","volume":"42","author":"Kim","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"107704","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Consortium","year":"2014","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.biopsych.2016.03.2104","article-title":"Pathway-Specific Dopamine Abnormalities in Schizophrenia","volume":"81","author":"Weinstein","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2004.01.036","article-title":"Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems","volume":"488","author":"Giorgetti","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neubiorev.2014.06.005","article-title":"Alterations in the serotonin system in schizophrenia: A systematic review and meta-analysis of postmortem and molecular imaging studies","volume":"45","author":"Selvaraj","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1523\/JNEUROSCI.6158-09.2010","article-title":"GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression","volume":"30","author":"Yoon","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/npp.2014.95","article-title":"Neurodevelopment, GABA system dysfunction, and schizophrenia","volume":"40","author":"Schmidt","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1038\/s41467-021-25353-5","article-title":"Ten-eleven translocation 1 mediated-DNA hydroxymethylation is required for myelination and remyelination in the mouse brain","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1046\/j.1471-4159.2000.0750889.x","article-title":"Regulation of neurotransmitter release by metabotropic glutamate receptors","volume":"75","author":"Cartmell","year":"2000","journal-title":"J. Neurochem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.schres.2005.04.001","article-title":"Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment","volume":"77","author":"Bishop","year":"2005","journal-title":"Schizophr. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1590\/1516-4446-2016-1969","article-title":"The role of the CNR1 gene in schizophrenia: A systematic review including unpublished data","volume":"39","author":"Santos","year":"2017","journal-title":"Braz. J. Psychiatry"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Goh, K.K., Chen, C.H., and Lane, H.Y. (2021). Oxytocin in Schizophrenia: Pathophysiology and Implications for Future Treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22042146"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2011.09.022","article-title":"The role of BDNF in the pathophysiology and treatment of schizophrenia","volume":"46","author":"Favalli","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"285","DOI":"10.9740\/mhc.2016.11.285","article-title":"Brain-derived neurotrophic factor and schizophrenia","volume":"6","year":"2016","journal-title":"Ment. Health Clin."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/7854_2018_88","article-title":"Cytokines, Oxidative Stress and Cellular Markers of Inflammation in Schizophrenia","volume":"44","author":"Upthegrove","year":"2020","journal-title":"Curr. Top Behav. Neurosci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00702-005-0358-5","article-title":"Interaction analysis between 5-HTTLPR and TNFA -238\/-308 polymorphisms in schizophrenia","volume":"113","author":"Pae","year":"2006","journal-title":"J. Neural. Transm."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrn2392","article-title":"Neuregulin 1 in neural development, synaptic plasticity and schizophrenia","volume":"9","author":"Mei","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev.pharmtox.42.082701.160735","article-title":"Glutamatergic mechanisms in schizophrenia","volume":"42","author":"Tsai","year":"2002","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ng1296","article-title":"Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia","volume":"36","author":"Emamian","year":"2004","journal-title":"Nat. Genet."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biopsych.2005.05.005","article-title":"Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families","volume":"58","author":"Schwab","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.biopsych.2007.06.005","article-title":"AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families","volume":"63","author":"Thiselton","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajmg.b.30481","article-title":"Towards understanding the schizophrenia code: An expanded convergent functional genomics approach","volume":"144B","author":"Balaraman","year":"2007","journal-title":"Am J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neuropharm.2012.08.015","article-title":"The involvement of Reelin in neurodevelopmental disorders","volume":"68","author":"Folsom","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/s41598-019-38490-1","article-title":"Elevated ubiquitinated proteins in brain and blood of individuals with schizophrenia","volume":"9","author":"Bousman","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/pgs.15.155","article-title":"Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response","volume":"17","author":"Huang","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.euroneuro.2005.09.004","article-title":"Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment","volume":"16","author":"Hwang","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0924-977X(99)00044-9","article-title":"Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients","volume":"10","author":"Scharfetter","year":"1999","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/BF02346178","article-title":"Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia","volume":"97","author":"Shaikh","year":"1996","journal-title":"Hum. Genet."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pnpbp.2011.11.018","article-title":"Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: Replication and exploration","volume":"37","author":"Hwang","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/FPC.0000000000000314","article-title":"Gene-gene interaction between DRD4 and COMT modulates clinical response to clozapine in treatment-resistant schizophrenia","volume":"28","author":"Rajagopal","year":"2018","journal-title":"Pharmacogenet. Genomics"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.pnpbp.2010.05.017","article-title":"Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia","volume":"34","author":"Xu","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0893-133X(98)00007-4","article-title":"Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients","volume":"19","author":"Masellis","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00213-012-2773-2","article-title":"Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia","volume":"224","author":"Rajkumar","year":"2012","journal-title":"Psychopharmacology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.neulet.2008.01.083","article-title":"Relationship between three serotonin receptor subtypes (HTR3A, HTR2A and HTR4) and treatment-resistant schizophrenia in the Japanese population","volume":"435","author":"Ji","year":"2008","journal-title":"Neurosci. Lett."},{"key":"ref_91","first-page":"11","article-title":"An association between serotonin receptor 3B gene (HTR3B) and treatment-resistant schizophrenia (TRS) in a Japanese population","volume":"70","author":"Ji","year":"2008","journal-title":"Nagoya J. Med. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jpsychires.2010.04.003","article-title":"Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics","volume":"44","author":"Kohlrausch","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"100038","DOI":"10.1016\/j.bionps.2021.100038","article-title":"Gene Expression Of Methylation Cycle And Related Genes In Lymphocytes And Brain Of Patients With Schizophrenia And Non-Psychotic Controls","volume":"5","author":"Sershen","year":"2021","journal-title":"Biomark. Neuropsychiatry"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1177\/0004563216686377","article-title":"Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms","volume":"54","author":"Akamine","year":"2017","journal-title":"Ann. Clin. Biochem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/schbul\/sbab092","article-title":"Derivation and Molecular Characterization of a Morphological Subpopulation of Human iPSC Astrocytes Reveal a Potential Role in Schizophrenia and Clozapine Response","volume":"48","author":"Akkouh","year":"2022","journal-title":"Schizophr. Bull."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0304-3940(03)00828-0","article-title":"An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients","volume":"349","author":"Hong","year":"2003","journal-title":"Neurosci. Lett."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Kinoshita, M., Numata, S., Tajima, A., Yamamori, H., Yasuda, Y., Fujimoto, M., Watanabe, S., Umehara, H., Shimodera, S., and Nakazawa, T. (2017). Effect of Clozapine on DNA Methylation in Peripheral Leukocytes from Patients with Treatment-Resistant Schizophrenia. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18030632"},{"key":"ref_98","first-page":"551","article-title":"Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients","volume":"21","author":"Ammar","year":"2021","journal-title":"Pharm. J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/YPG.0000000000000139","article-title":"Cigarette smoking has a differential effect on the plasma level of clozapine in Taiwanese schizophrenic patients associated with the CYP1A2 gene -163A\/C single nucleotide polymorphism","volume":"26","author":"Huang","year":"2016","journal-title":"Psychiatr. Genet."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41398-022-01884-3","article-title":"Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders","volume":"12","author":"Bousman","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"ref_101","first-page":"267","article-title":"Association of Disrupted in Schizophrenia 1 (DISC1) missense variants with ultra-resistant schizophrenia","volume":"11","author":"Mouaffak","year":"2011","journal-title":"Pharm. J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/FPC.0b013e32832b9cfc","article-title":"The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation","volume":"19","author":"Zuo","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jpsychires.2010.01.002","article-title":"Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response","volume":"44","author":"Souza","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2217\/14622416.9.10.1429","article-title":"G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics","volume":"9","author":"Kohlrausch","year":"2008","journal-title":"Pharmacogenomics"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41398-020-00888-1","article-title":"Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients-a genome-wide association study adjusting for smoking habits","volume":"10","author":"Smith","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.schres.2011.08.007","article-title":"The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response","volume":"132","author":"Lett","year":"2011","journal-title":"Schizophr. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2217\/pgs.10.179","article-title":"Association of an UCP4 (SLC25A27) haplotype with ultra-resistant schizophrenia","volume":"12","author":"Mouaffak","year":"2011","journal-title":"Pharmacogenomics"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000026689","article-title":"Association study of apolipoprotein E epsilon4 with clinical phenotype and clozapine response in schizophrenia","volume":"42","author":"Hong","year":"2000","journal-title":"Neuropsychobiology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00001756-199901180-00011","article-title":"No evidence for association of serotonin-2A receptor variant (102T\/C) with schizophrenia or clozapine response in a Chinese population","volume":"10","author":"Lin","year":"1999","journal-title":"Neuroreport"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ajmg.1320600611","article-title":"Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients","volume":"60","author":"Shaikh","year":"1995","journal-title":"Am. J. Med. Genet."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0920-9964(99)00170-X","article-title":"Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response","volume":"44","author":"Tsai","year":"2000","journal-title":"Schizophr. Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0920-9964(00)00127-4","article-title":"Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response","volume":"49","author":"Tsai","year":"2001","journal-title":"Schizophr. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0920-9964(02)00531-5","article-title":"No association of tumor necrosis factor alpha gene polymorphisms with schizophrenia or response to clozapine","volume":"65","author":"Tsai","year":"2003","journal-title":"Schizophr. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00213-006-0482-4","article-title":"Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication","volume":"188","author":"Zai","year":"2006","journal-title":"Psychopharmacology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0304-3940(99)01000-9","article-title":"No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response","volume":"280","author":"Bolonna","year":"2000","journal-title":"Neurosci. Lett."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00041444-200112000-00007","article-title":"Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia","volume":"11","author":"Hong","year":"2001","journal-title":"Psychiatr. Genet."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/sj.mp.4000288","article-title":"The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: A haplotype relative risk study and association with clozapine response","volume":"3","author":"Malhotra","year":"1998","journal-title":"Mol. Psychiatry."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0920-9964(00)00016-5","article-title":"Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia","volume":"47","author":"Masellis","year":"2001","journal-title":"Schizophr. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00213-008-1193-9","article-title":"Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response","volume":"200","author":"Souza","year":"2008","journal-title":"Psychopharmacology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s11064-007-9521-8","article-title":"Molecular genetics of monoamine transporters: Relevance to brain disorders","volume":"33","author":"Haddley","year":"2008","journal-title":"Neurochem. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF03033354","article-title":"Dopaminergic dysbalance in distinct basal ganglia neurocircuits: Implications for the pathophysiology of Parkinson\u2019s disease, schizophrenia and attention deficit hyperactivity disorder","volume":"10","author":"Riederer","year":"2006","journal-title":"Neurotox. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2217\/14622416.8.10.1337","article-title":"Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: An association study","volume":"8","author":"Zhang","year":"2007","journal-title":"Pharmacogenomics"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.neuropharm.2010.10.021","article-title":"Epigenetic GABAergic targets in schizophrenia and bipolar disorder","volume":"60","author":"Guidotti","year":"2011","journal-title":"Neuropharmacology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2217\/pgs.09.51","article-title":"ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients","volume":"10","author":"Consoli","year":"2009","journal-title":"Pharmacogenomics"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1742-7843.2008.00298.x","article-title":"Antipsychotic drugs inhibit the function of breast cancer resistance protein","volume":"103","author":"Wang","year":"2008","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.euroneuro.2017.03.005","article-title":"The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophrenia","volume":"27","author":"Einoch","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.freeradbiomed.2008.12.015","article-title":"Mitochondrial UCP4 attenuates MPP+\u2014And dopamine-induced oxidative stress, mitochondrial depolarization, and ATP deficiency in neurons and is interlinked with UCP2 expression","volume":"46","author":"Chu","year":"2009","journal-title":"Free Radic. Biol. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"37391","DOI":"10.1074\/jbc.M605552200","article-title":"Mitochondrial uncoupling protein-4 regulates calcium homeostasis and sensitivity to store depletion-induced apoptosis in neural cells","volume":"281","author":"Chan","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0074-7742(04)59011-6","article-title":"Mitochondria, synaptic plasticity, and schizophrenia","volume":"59","author":"Laifenfeld","year":"2004","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1017\/S1461145707008401","article-title":"Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications","volume":"11","author":"Ng","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0896-6273(00)81049-1","article-title":"Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K+ channels","volume":"24","author":"Poliak","year":"1999","journal-title":"Neuron"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature07239","article-title":"Rare chromosomal deletions and duplications increase risk of schizophrenia","volume":"455","author":"Consortium","year":"2008","journal-title":"Nature"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1017\/S1461145704004699","article-title":"Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response","volume":"7","author":"Lemonde","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1097\/00001756-200006260-00018","article-title":"Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment","volume":"11","author":"Zill","year":"2000","journal-title":"Neuroreport"},{"key":"ref_135","first-page":"29","article-title":"Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders","volume":"4","author":"Lee","year":"2004","journal-title":"Pharm. J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrn3120","article-title":"Linking neurodevelopmental and synaptic theories of mental illness through DISC1","volume":"12","author":"Brandon","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1503\/jpn.120007","article-title":"Abnormal synaptic pruning in schizophrenia: Urban myth or reality?","volume":"37","author":"Boksa","year":"2012","journal-title":"J. Psychiatry Neurosci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0022-3956(82)90038-3","article-title":"Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence?","volume":"17","author":"Feinberg","year":"1982","journal-title":"J. Psychiatr. Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eurpsy.2015.01.008","article-title":"Dysbindin (DTNBP1) variants are associated with hallucinations in schizophrenia","volume":"30","author":"Cheah","year":"2015","journal-title":"Eur. Psychiatry"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Burke, R.E. (2006). GDNF as a candidate striatal target-derived neurotrophic factor for the development of substantia nigra dopamine neurons. J. Neural. Transm. Suppl., 41\u201345.","DOI":"10.1007\/978-3-211-45295-0_8"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/sj.mp.4000835","article-title":"Evidence for association of the myo-inositol monophosphatase 2 (IMPA2) gene with schizophrenia in Japanese samples","volume":"6","author":"Yoshikawa","year":"2001","journal-title":"Mol. Psychiatry"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1523\/JNEUROSCI.21-15-05429.2001","article-title":"Kir4.1 potassium channel subunit is crucial for oligodendrocyte development and in vivo myelination","volume":"21","author":"Neusch","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"33097","DOI":"10.1074\/jbc.274.46.33097","article-title":"Characterization of four mammalian numb protein isoforms. Identification of cytoplasmic and membrane-associated variants of the phosphotyrosine binding domain","volume":"274","author":"Dho","year":"1999","journal-title":"J. Biol. Chem.."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.2319-13.2014","article-title":"NFIB-mediated repression of the epigenetic factor Ezh2 regulates cortical development","volume":"34","author":"Piper","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1128\/MCB.25.2.685-698.2005","article-title":"The transcription factor gene Nfib is essential for both lung maturation and brain development","volume":"25","author":"Plachez","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"17998","DOI":"10.1073\/pnas.0910297106","article-title":"Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments","volume":"106","author":"Etherton","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/neuro.02.006.2008","article-title":"Altered Excitatory-Inhibitory Balance in the NMDA-Hypofunction Model of Schizophrenia","volume":"1","author":"Kehrer","year":"2008","journal-title":"Front. Mol. Neurosci."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.brainres.2011.06.042","article-title":"Serine proteases, serine protease inhibitors, and protease-activated receptors: Roles in synaptic function and behavior","volume":"1407","author":"Almonte","year":"2011","journal-title":"Brain Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1038\/s41467-021-23735-3","article-title":"TET1-mediated DNA hydroxymethylation regulates adult remyelination in mice","volume":"12","author":"Moyon","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/glia.22649","article-title":"Dynamics of ten-eleven translocation hydroxylase family proteins and 5-hydroxymethylcytosine in oligodendrocyte differentiation","volume":"62","author":"Zhao","year":"2014","journal-title":"Glia"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e2983","DOI":"10.1590\/1518-8345.2222.2983","article-title":"Prevalence of polymorphisms in the ANKK1, DRD2, DRD3 genes and metabolic syndrome in refractory schizophrenia","volume":"26","author":"Pinto","year":"2018","journal-title":"Rev. Lat. Am. Enfermagem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.jcp.0000177668.42640.fe","article-title":"Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients","volume":"25","author":"Fehsel","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_153","first-page":"325","article-title":"Clozapine-induced agranulocytosis in schizophrenic Caucasians: Confirming clues for associations with human leukocyte class I and II antigens","volume":"7","author":"Dettling","year":"2007","journal-title":"Pharm. J."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S1461145798001023","article-title":"An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201","volume":"1","author":"Amar","year":"1998","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2370.1998.00091.x","article-title":"HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients","volume":"25","author":"Valevski","year":"1998","journal-title":"Eur. J. Immunogenet."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1001\/archpsyc.1990.01810220061007","article-title":"HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia","volume":"47","author":"Lieberman","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/YPG.0000000000000053","article-title":"Polymorphisms of the leptin and HTR2C genes and clozapine-induced weight change and baseline BMI in patients with chronic schizophrenia","volume":"24","author":"Kang","year":"2014","journal-title":"Psychiatr. Genet."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/JCP.0000000000000386","article-title":"The Relationships of Obesity-Related Genetic Variants With Metabolic Profiles and Response to Metformin in Clozapine-Treated Patients with Schizophrenia","volume":"35","author":"Chen","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.pnpbp.2014.08.015","article-title":"Association between SREBF2 gene polymorphisms and metabolic syndrome in clozapine-treated patients with schizophrenia","volume":"56","author":"Yang","year":"2015","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"R287","DOI":"10.1152\/ajpregu.00123.2002","article-title":"Physiological significance of alpha(2)-adrenergic receptor subtype diversity: One receptor is not enough","volume":"283","author":"Philipp","year":"2002","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.psychres.2015.02.021","article-title":"Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia","volume":"227","author":"Suzuki","year":"2015","journal-title":"Psychiatry Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1192\/bjp.bp.113.138578","article-title":"A neurobiological hypothesis for the classification of schizophrenia: Type A (hyperdopaminergic) and type B (normodopaminergic)","volume":"205","author":"Howes","year":"2014","journal-title":"Br. J. Psychiatry"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0006-3223(98)00187-5","article-title":"Serotonergic basis of antipsychotic drug effects in schizophrenia","volume":"44","author":"Lieberman","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00213-009-1612-6","article-title":"Role of cannabis and endocannabinoids in the genesis of schizophrenia","volume":"206","author":"Viveros","year":"2009","journal-title":"Psychopharmacology"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1016\/j.rbp.2012.07.003","article-title":"The endocannabinoid system and its role in schizophrenia: A systematic review of the literature","volume":"34","author":"Ferretjans","year":"2012","journal-title":"Braz. J. Psychiatry"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"543893","DOI":"10.3389\/fpsyt.2020.543893","article-title":"Non-Coding RNAs in Psychiatric Disorders and Suicidal Behavior","volume":"11","author":"Yoshino","year":"2020","journal-title":"Front. Psychiatry"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1517\/17425255.2015.1075003","article-title":"Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: An update","volume":"11","author":"Sriretnakumar","year":"2015","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs.14.150","article-title":"COMT Val158Met and 5-HT1A-R -1019 C\/G polymorphisms: Effects on the negative symptom response to clozapine","volume":"16","author":"Bosia","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/acps.12854","article-title":"Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia","volume":"137","author":"Galling","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ejps.2003.09.010","article-title":"CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients","volume":"20","author":"Koopmans","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1177\/00912700122010717","article-title":"Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations","volume":"41","author":"Olesen","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.1365-2125.1997.t01-1-00605.x","article-title":"The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine","volume":"44","author":"Eiermann","year":"1997","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4088\/JCP.v62n1102","article-title":"Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics","volume":"62","author":"Olsson","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nature11147","article-title":"Immune self-reactivity triggered by drug-modified HLA-peptide repertoire","volume":"486","author":"Illing","year":"2012","journal-title":"Nature"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.schres.2021.05.010","article-title":"Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment","volume":"232","author":"Lisoway","year":"2021","journal-title":"Schizophr. Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/epi.16053","article-title":"Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States","volume":"60","author":"Choi","year":"2019","journal-title":"Epilepsia"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/mp.2015.16","article-title":"Evaluating historical candidate genes for schizophrenia","volume":"20","author":"Farrell","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1176\/appi.ajp.2018.18070881","article-title":"No Support for Historical Candidate Gene or Candidate Gene-by-Interaction Hypotheses for Major Depression Across Multiple Large Samples","volume":"176","author":"Border","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1590\/1516-4446-2020-1646","article-title":"Ditching candidate gene association studies: Lessons from psychiatric genetics","volume":"43","author":"Duarte","year":"2021","journal-title":"Braz. J. Psychiatry"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/add.15680","article-title":"Genome-wide analysis reveals genetic overlap between alcohol use behaviours, schizophrenia and bipolar disorder and identifies novel shared risk loci","volume":"117","author":"Karadag","year":"2022","journal-title":"Addiction"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Zhu, Z., Anttila, V., Smoller, J.W., and Lee, P.H. (2018). Statistical power and utility of meta-analysis methods for cross-phenotype genome-wide association studies. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193256"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41586-022-04434-5","article-title":"Mapping genomic loci implicates genes and synaptic biology in schizophrenia","volume":"604","author":"Trubetskoy","year":"2022","journal-title":"Nature"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1017\/S0033291720005334","article-title":"Genetic architecture of schizophrenia: A review of major advancements","volume":"51","author":"Legge","year":"2021","journal-title":"Psychol. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13073-020-00742-5","article-title":"Polygenic risk scores: From research tools to clinical instruments","volume":"12","author":"Lewis","year":"2020","journal-title":"Genome. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3389\/fphar.2019.00617","article-title":"Treatment-Resistant Schizophrenia: Insights From Genetic Studies and Machine Learning Approaches","volume":"10","author":"Pisanu","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1005702","DOI":"10.3389\/fphar.2022.1005702","article-title":"Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives","volume":"13","author":"Jiao","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/3\/689\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:52:04Z","timestamp":1760122324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/3\/689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":186,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["genes14030689"],"URL":"https:\/\/doi.org\/10.3390\/genes14030689","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,10]]}}}